Event Content

Cytiva helps the biopharma industry reduce Scope 3 emissions with strategies such as embedding ecodesign principles across our product portfolio and advancing process intensification approaches. Through the use of primary emissions data, we empower manufacturers to make smarter, data-driven sustainability ...

Single-use bottles continue to play a significant role in biomanufacturing, yet they often fall short in supporting closed, aseptic, and scalable fluid management. This presentation explores how automated single-use bottle filling bridges that gap. By combining process flexibility with cGMP compliance, aut...

This session will begin with an introduction highlighting the critical importance of EcoDesign and carbon footprint reduction in the industry. The presentation will outline Sartorius' comprehensive sustainability strategy, including their ambitious 2045 net-zero carbon commitment and provide an overview of...

• Alternative Approaches to Boost Patient Enrolment Amid Recruitment Challenges • How the Rising Pressures of Patient Recruitment Are Challenging Traditional Enrolment Methods

During the past several decades, drug development sponsors have implemented a number of approaches to reduce operating inefficiencies focusing largely on within-function process improvements.  Recently, sponsors have turned their attention to reducing the inefficiencies between  functional collaborations....

Exploring how the growth of manufacturing capabilities in Latin America creates export opportunities, strengthens global supply chains, and offers new market access for U.S. pharma. Evaluating Latin America's potential to become a leading player in the pharmaceutical industry and how this growth translate...

Drug/device combination products are transforming healthcare, but many pharma companies face hidden challenges that slow their progress. Misaligned priorities, complex regulatory requirements, and gaps in device-specific knowledge create costly delays and inefficiencies.
This session explores the t...

This session will explore the latest trends and growing complexities in parenteral drug packaging and labelling. Lars Skole will address challenges such as the rise of new medicines, self-administered treatments, international market demands, and price pressures, offering insights into how pharmaceutical d...

Packaging is a key factor in the production, commercialization, distribution, and proper preservation of pharmaceutical products. Flexible packaging has always been a good alternative because, by combining different materials, we can create unique packaging that unifies the best properties of each material...

Subcutaneous technologies have demonstrated real advantages in healthcare provision and have become a growth driver that doesn’t look to slow with upcoming adoption by weight-loss, oncology and immunology therapies. By advancing biologic therapies to subcutaneous presentations, we not only enhance patient ...

As biopharma companies increasingly seek to optimize the drug development timeline, China has emerged as a cost-effective biomanufacturing hub for both the rapidly growing Chinese market and the rest of the world. New localization guidelines set by the NMPA’s Center for Drug Evaluation encourage global com...

Join our Pharma Awards Winner as we Recognise their achievements in accelerating innovation and improving patient outcomes across healthcare

KBI Biopharma’s cell line development services, powered by Selexis®, have been at the forefront of innovation for the last two decades. We are introducing the latest version of proprietary SURE CHO-M technology, which uses a transposase-based semi-targeted integration method and provides high productivity ...

During pharmaceutical product development, Boehringer Ingelheim generates hundreds of thousands of documents, each containing valuable knowledge and problem-solving strategies. • The challenge is to make this knowledge accessible within the company to avoid redundant efforts. To address this, Boehrin...

In the rapidly evolving digital ecosystem of pharmaceutical development, there is a growing importance for the integration and management of diverse data to help drive affordable success. This presentation will delve into the realm of big data and how comprehensive data management impacts parameter pred...

Excipients for pharmaceutical processes – How to identify opportunities for novel excipients that solve formulation and process challenges"; Needs of the industry for novel excipients, ways to identify current gaps and work together to resolve them, 1-2 key examples of common process challenges that might ...

Join us for a series of rapid-fire talks on disruptive manufacturing technologies. • AI - Unleashing the potential of AI in pharmaceutical manufacturing to streamline processes, enhance efficiency, and ensure product quality • Advanced Manufacturing - Delving into the latest advanced manufacturing ...

Drug development, particularly of biologics can be expensive and run over several years. One of the challenges for formulation and clinical development teams is identifying devices for use in early formulation and clinical studies, where the performance characteristics and clinical safety are being assesse...

Bormioli Pharma has developed a solid and extensive patient-centric innovation program intended to advise the pharma industry along the entire drug development process, from early stage compatibility assessment up to the production of parts needed for drug fileing, clinical trials and commercialization. ...

Sterile pharmaceutical production is expected to grow by over 50% in the next seven years, driven by new demand for recombinant antibodies and small molecules. Consequently, the fill/finish stage in pharmaceutical manufacturing is becoming a bottleneck in the pharmaceutical production . Health authorities ...

This session will explore: • High Oxygen, CO2 and UV Barrier suitable for Biologics and Cell & Gene Therapies • Extremely Low Inorganic Extractables Suitable for Biologics and Cell & Gene Therapies • New Container Closure Integrity (CCI) Data at Deep Cold Storage (-80 degree C)

After years of investment in R&D, pharmaceutical companies have brought to the market a growing number of new therapies based on mRNA or viral vector technology, which require storage at freezing temperatures. Deep cold storage poses great challenges to the primary packaging container. This session will ...

OXYCAPT
• OXYCAPT Multilayer Plastic Vial for Biologics and Gene/Cell Therapy • High Oxygen, CO2 and UV Barrier suitable for Biologics and Gene/Cell Therapy • Extremely Low Inorganic Extractables Suitable for Biologics and Gene/Cell Therapy • New Container Closure Integrity (CCI) Data ...

Ferrar’s objective is to lead change towards more sustainable production by adopting criteria and commitments that minimize the environmental footprint of its containers and packaging
For this, it has designed the Sustainable Packaging Model, with the participation of Anthesis Lavola.
The Mo...

• Ensuring quality and compliance in bio-manufacturing • Closing gaps in development data prior to the first GMP production • Adjusting manufacturing processes throughout the course of a site-to-site transfer • Fulfilling special requirements on container closure systems for biologics • ...

• GUCY2C is a mucosally-restricted, immunologically compartmentalized self-antigen overexpressed in GI adenocarcinomas • GUCY2C Vaccination in MRD (minimal residual disease) setting for recurrence prevention • GUCY2C adoptive cell therapy for treatment of metastatic GI cancers

In pharma, it is essential to identify the right partner to ensure a successful outcome. Time and time again, mistakes have been made in this process, causing clinical studies to fail and for the company to take a heavy hit. Want to avoid this? join our one-hour masterclass where we will devise a checklist...

Pharmaceutical and other healthcare innovations have extended and improved countless lives in recent decades. Today, advanced manufacturing technologies such as pharmaceutical continuous manufacturing are gaining increasing interest for their potential to serve as one more way to improve global health by b...

With US Pharma pledging to become net-zero by 2050, you must have the right processes. Join our focused panel where our experts will discuss the best ways to implement ESG in your organization: • Defining ESG in Pharma to understand what makes it different from other industries • Establishing what i...

Human Factors Engineering (HFE) process participates in the product development for a safe and effective use by the end-user population. HFE data are under agencies' scrutiny as part of the design control of a drug - device combination product. Timely planning can be challenging during combination product ...

In 2022, the final recommendations of the Product Quality Research Institute were published for Parenteral Drug Products. Apart from the wealth of information and considerations on design of extractable & leachable studies for parenteral drug products in general, it also contains valuable information on sp...

New therapeutic treatments or prophylactic vaccines rely on more complicated drug formulations, often based on biologics. These drugs are highly sensitive and might require low temperature storage to keep them stable over shelf life. These extreme cold supply chain processes, something up to -80°C, provide...

Rubber compound FM30 is a well know compound offered by all big syringe manufacturers these days. It is a low extractable compound with a high gas permeability and is suitable for producing both a needle shield and a tip cap which are sterilized by ethylene oxide. There is a clear trend to move from the ...

• Digitalization in biopharma is more complex than just replacing paper documents with electronic counterparts or hiring data scientist • In the context of bioprocessing, the industry needs a better way to transition quickly from lab to clinical to commercial manufacturing • Speed to clinic require...

In recent years, the standardization of biologics manufacturing processes has given product developers multiple viable options for producing biologics. These options include building an in-house production system or partnering with a contract biologics manufacturer. Although building in-house does offer th...

Hydrophilic polymer matrix systems are widely used in oral controlled drug delivery because of their flexibility to obtain a desirable drug release profile, cost effectiveness, and broad regulatory acceptance.

Hydroxypropyl methyl cellulose (HPMC) is the key matrix former used in the majority ...

The pipeline for advanced genetic therapies has grown exponentially since 2014, and now totals over 3,500 different developmental candidates. This session provides a comprehensive global snapshot of this R&D landscape, spanning gene, cell, and RNA-based drug modalities. This includes analysis of drug pipel...

In this webinar, originally broadcast as part of the Pharmapack Europe show, Felix Georg Müller, CEO & Co-Founder, plus10 GmbH introduces the company's innovative and GMP-compliant AI-tools for automated pharmaceutical production and packaging lines. The focus of the presentation is a detailed best practic...

In this webinar, originally broadcast as part of Pharmapack Europe 2022, Chris Muenzer, Vice President of Innovation & Development, Haselmeier, a medmix Brand discusses how development of an integrated drug delivery device is a complex exercise that requires expertise in medical device engineering and phar...

In this webinar, originally broadcast as a part of Pharmapack Europe, speaker Holger Krenz, Vice President Applications Development Europe, SiO2 Materials Science discusses: • Introduction SIO2 Materials Science / Technology, defect modes biological drugs vs. primary packaging • Case Study Novartis...

In this webinar, originally part of Pharmapack Europe 2022, Bernd Garska, Technical Marketing Manager Healthcare EMEA, Covestro AG discusses how until now, drug delivery devices would require tedious sorting with a variety of materials used in various components. Now, with an all-polycarbonate device, mini...

Discuss strategies and methodologies to develop scalable, robust, and cost-effective manufacturing processes for allogeneic cell therapies Showcase how induced pluripotent stem cells (iPSC) are being used as renewable sources of allogeneic cancer therapies Demonstrate the criticality of GMP manufacturing...

Q&A featuring Raman Sehgal, host of Molecule to Market and Stephanie Watson, Global Strategy and Commercial Planning Lead at Pfizer CentreOne Diving into the biggest challenges the supply chain are currently facing, as well as potential solutions Dissect successful responses and shed light on the future tr...

This discussion will focus on four critical areas for process development and overall product life cycle management: Quality, Scalability, COGS and Sustainability Strategies for accelerating process development in efforts to initiate clinical trials quicker will also be discussed Examples, from both ...

This presentation will provide an overview of the differences and similarities of E&L requirements between pharmaceutical products and medical devices. The key elements regarding E&L testing design of combination products will be discussed. Several case studies on the extractables and leachables testing of...